Format

Send to

Choose Destination
ACS Infect Dis. 2019 Feb 8;5(2):152-157. doi: 10.1021/acsinfecdis.8b00298. Epub 2018 Dec 13.

Drug Discovery for Kinetoplastid Diseases: Future Directions.

Author information

1
Novartis Institute for Tropical Diseases (NITD) , 5300 Chiron Way , Emeryville , California 94608 , United States.
2
University of Glasgow , University Place , Glasgow G12 8TA , United Kingdom.
3
Immuno-oncology , Novartis Institutes for Biomedical Research (NIBR) , 250 Massachusetts Avenue , Cambridge , Massachusetts 02139 , United States.
4
Autoimmunity, Transplantation and Inflammation , NIBR , Fabrikstrasse 2 , CH-4056 Basel , Switzerland.
5
Global Drug Development, Novartis Pharma, Forum 1, CH-4056 Basel , Switzerland.
6
School of Medicine, Addis Ababa University , P.O. Box 28017 code 1000 , Addis Ababa , Ethiopia.
7
London School of Hygiene and Tropical Medicine , Keppel Street , London WC1E 7HT , United Kingdom.
8
Independent Consultant, Chemic Des Tulipiers 9 , 1208 Geneva , Switzerland.
9
Swiss Tropical and Public Health Institute, Socinstrasse 57, 4501 Basel, Switzerland; University of Basel , CH 4000 Basel , Switzerland.
10
Laboratory of Clinical Immunology , Oswaldo Cruz Institute , FIOCRUZ-RJ, Av. Brasil 4365 , Cep: 21040-900 , Rio de Janeiro -RJ, Brazil.
11
Faculty of Medicine of Petropolis , University in Petròpolis , Av. Barao do Rio Branco 1003 , Cep: 25680-120 , Petropolis -RJ, Brazil.
12
University of York , Wentworth Way Heslington , York YO10 5DD , United Kingdom.
13
Drugs for Neglected Diseases initiative, 15 Chemin Louis-Dunant , 1202 Geneva , Switzerland.
14
National Institute of Allergy and Infectious Diseases , 4 Memorial Drive , Bethesda , Maryland 20892 , United States.
15
University of Pennsylvania , 380 South University Avenue , Philadelphia , Pennsylvania 19104 , United States.
16
Institut Pasteur, 25 Rue du Docteur Roux , 75015 Paris , France.
17
University of Georgia , Coverdell Center, 500 DW Brooks Dr , Athens , Georgia 30602 , United States.

Abstract

Kinetoplastid parasites have caused human disease for millennia. Significant achievements have been made toward developing new treatments for leishmaniasis (particularly on the Indian subcontinent) and for human African trypanosomiasis (HAT). Moreover, the sustained decrease in the incidence of HAT has made the prospect of elimination a tantalizing reality. Despite the gains, no new chemical or biological entities to treat kinetoplastid diseases have been registered in more than three decades, and more work is needed to discover safe and effective therapies for patients with Chagas disease and leishmaniasis. Advances in tools for drug discovery and novel insights into the biology of the host-parasite interaction may provide opportunities for accelerated progress. Here, we summarize the output from a gathering of scientists and physicians who met to discuss the current status and future directions in drug discovery for kinetoplastid diseases.

PMID:
30543391
DOI:
10.1021/acsinfecdis.8b00298
Free full text

Supplemental Content

Full text links

Icon for American Chemical Society Icon for London School of Hygiene and Tropical Medicine
Loading ...
Support Center